What did @dr.jennifer.mercier actually say?
She claimed the FDA "has removed the black box warning on many forms of hormone therapy for women" and called it "a huge step forward" in validating bioidentical and well-timed hormone therapy. She also credited FDA Commissioner Marty Makary's book Blind Spots as a kind of early prophecy for this change, and used the announcement to promote her practice's hormone and thyroid panels.
The specific clinical framing she offered, that hormone therapy is safe "when started within ten years of menopause or before age 60," is actually the most defensible thing she said. That language comes directly from what researchers call the "timing hypothesis" or "window of opportunity" concept in menopause medicine. The rest of her framing, however, deserves scrutiny.
Does the science back this up?
The timing hypothesis is well-supported. The broader claim that the FDA has formally removed black-box warnings is not, at least not yet, and conflating the two is a problem.
The timing hypothesis, sometimes called the critical window hypothesis, is supported by data from the Women's Health Initiative Memory Study reanalysis, the KEEPS trial (Harman et al., 2014, JAMA Internal Medicine), and the ELITE trial (Hodis et al., 2016, New England Journal of Medicine). These studies consistently show that estrogen therapy initiated close to menopause carries a more favorable cardiovascular and cognitive risk profile than therapy started a decade or more later. The North American Menopause Society and the Endocrine Society both endorse this framing in their current guidelines.
What the science does not yet do is erase the black-box warning. The FDA has been reviewing HRT labeling, and there has been advocacy, including from the Menopause Society, to modernize the warning. But as of the most recent publicly available FDA actions, no formal removal of the black-box warning has been finalized and published in the Federal Register.
What did they get wrong (or right)?
She got the clinical framing right and the regulatory claim wrong, and those are not equally weighted errors given that 51,000 people are watching.
Saying "the FDA has removed the black box warning" as a completed fact is the core problem here. What appears to have happened is that the FDA proposed or initiated a labeling review process, which is meaningfully different from actually removing a black-box warning. The FDA's formal labeling change process involves a proposed rule, public comment period, and final rule publication. None of that appears to have been completed. Describing a regulatory process as a finished outcome misleads patients who may now believe a risk designation has officially changed when it has not.
She also says this "acknowledges that bioidentical hormone therapy is safe," which blurs an important line. FDA labeling changes apply to approved drug products, not to compounded bioidentical preparations, which carry their own separate and unresolved regulatory status. Those are not the same thing, and treating them as equivalent is inaccurate.
Credit where it is due: the timing window she described (within 10 years of menopause or before age 60) reflects current evidence accurately.
What should you actually know?
If you have been avoiding HRT because of the 2002 WHI headlines, your hesitation may be based on outdated data, but that does not mean the regulatory landscape has already changed.
The 2002 Women's Health Initiative study alarmed a generation of clinicians and patients by suggesting HRT raised breast cancer and cardiovascular risks. Subsequent reanalyses, including work by Manson et al. (2013, JAMA Internal Medicine), showed those risks were heavily skewed by the age of participants, most of whom were in their 60s and 70s, well outside the timing window. For women who start hormone therapy closer to menopause, the risk-benefit picture looks considerably different.
The Menopause Society has publicly supported modernizing the black-box warning and submitted comments to the FDA to that effect. That advocacy is real and ongoing. But advocacy is not action. Patients should ask their provider what has actually changed in FDA labeling versus what is being proposed, and they should know that compounded bioidentical hormones are regulated differently than FDA-approved hormone therapies. Those distinctions matter clinically.